Is IXJ a good investment?

iShares Global Healthcare ETF (IXJ) is a healthcare and biotech ETF. As of September 11, 2026, ETF Copilot scores IXJ 5.4 out of 10 — highest on Risk (7.2), lowest on Return (2.2). It trades at 26.5 times earnings, against its own median of 24.1. Its ten largest holdings are 46% of the fund.

Updated September 11, 2026

How is IXJ rated? ETF Copilot scores iShares Global Healthcare ETF (IXJ) 5.4 out of 10

As of September 11, 2026, ETF Copilot scores iShares Global Healthcare ETF (IXJ) 5.4 out of 10 overall.

ETF Copilot scores (0–10 scale, higher is better):

Overall: 5.4 / 10
Growth: 6.8 / 10
Valuation: 5.9 / 10
Risk: 7.2 / 10
Quality: 5.7 / 10
Return: 2.2 / 10

What is IXJ's expense ratio? 0.38% a year

As of September 11, 2026, IXJ charges 0.38% a year, yields 1.81% and holds $4.3B in assets across 121 positions.

iShares Global Healthcare ETF (IXJ) — cost, income and size
Measure	IXJ
Expense ratio	0.38%
Dividend yield	1.81%
Assets under management	$4.3B
Holdings	121

Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.

What stands out in IXJ's data

Global healthcare sector stocks, from drugmakers to medical equipment.

Analysts see faster earnings growth ahead than the typical health-sector fund — more potential upside from the same holdings.

A forward growth estimate of 18% sits above the peer median of 16% and well above the fund's own 10% historical median. Holds 121 stocks.

A global health-sector sleeve that can steady a portfolio through market cycles.

Why did IXJ move this week? It fell 5.0% in the week to September 11, 2026 — Novartis and Amgen drove it

IXJ fell 5.0% in the week to September 11, 2026. The holdings that moved it most were Novartis (−15.2%), Amgen (−15.0%) and Eli Lilly (−3.8%); HCA Healthcare (+4.3%) pushed the other way.

Is IXJ expensive right now? It trades at 26.5 times earnings, against its own median of 24.1

As of September 11, 2026, IXJ is more expensive than 81% of its own 114 monthly readings since 2017 — 92 of those months were cheaper than today.

Trailing twelve-month, computed by ETF Copilot from the fund's holdings rather than quoted from a data provider, and rebuilt nightly.

What's inside IXJ?

What's inside IXJ: Size (Large 91%, Mid 9%, Small 1%); Geography (International 25%, US 75%); AI 0.3%.

What are IXJ's top holdings? The ten largest are 46% of the fund

Eli Lilly, Johnson & Johnson, Abbvie, Merck, UnitedHealth, Roche, Novartis, AstraZeneca, Thermo Fisher Scientific and Amgen are IXJ's largest holdings, in that order.

Less concentrated than 60% of Healthcare & Biotech ETFs.

Half of IXJ's weight sits in its 12 largest positions, and once those weights are taken into account it behaves like 30 equally weighted holdings.

Cite this

ETF Copilot, “iShares Global Healthcare ETF (IXJ) scores and holdings analysis”, as of September 11, 2026.
https://etf-copilot.com/etf/ixj